Evidence map›Paper›PMID 40948742›Full record

ReviewFrontiers in immunology2025

S100 proteins as a key immunoregulatory mechanism for NLRP3 inflammasome.

Shahinur Acter, Qing Lin

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Shahinur ActerDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.
Qing LinDepartment of Anesthesiology and Critical Care Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Funding

Resistin regulates NLRP3 inflammasome in pulmonary hypertensionR01HL166717 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Roger A Johns, Qing Lin · 2023 to 2026
$2.8M
American Heart Association-American Stroke Association 938614NHLBI NIH HHS R01 HL166717
6 · The paper itself

Abstract

The S100 superfamily of proteins consists of Ca2+-binding proteins characterized by the EF-hand motif. Certain members of this protein family, such as S100A8, S100A9, and S100A12, have been effectively utilized as biomarkers for the detection and evaluation of prognosis in immunological diseases. These proteins are also identified as damage-associated molecular pattern (DAMP) molecules, which exhibit significant upregulation in various autoimmune disorders, cancers, and neurodegenerative diseases. Following tissue injury, necrotic or immune cells release or secrete DAMPs to initiate inflammatory responses. This signaling further creates autocrine and paracrine positive feedback loops that amplify and sustain the inflammatory response. The NLRP3 inflammasome pathway is a pivotal component in these DAMP-induced immune regulatory mechanisms. This review summarizes the regulatory roles of S100 protein family in NLRP3 inflammasome signaling and their functions in innate and adaptive immunity, with an emphasis on pulmonary hypertension. Moreover, we examine the interactive feedback mechanisms among NLRP3 inflammasome, S100A8/A9, and Gasdermin D, exploring their implications in autoimmune diseases.

Indexed as

InflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinS100 ProteinsAlarminsAnimalsAutoimmune DiseasesHumansImmunity, InnateSignal TransductionAlarminsInflammasomesNLR Family, Pyrin Domain-Containing 3 ProteinNLRP3 protein, humanS100 ProteinsDAMPgasdermin Dinflammasomepulmonary hypertensionS100A8S100A9

Identifiers

PMID40948742
PMCPMC12422935

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.